Abstract:OBJECTIVE:p53 gene, as "the guardian of the genome", is the most widely studied tumor suppressor gene. Previous studies have shown that about 50 percent of tumors have P53 dysfunction. This article aims to retrospectively analyze the correlation between p53 rs1625895 polymorphism and the prognosis of patients with diffuse large B-cell lymphoma (DLBCL).METHODS:PCR combined with Sanger sequencing were used to detect rs1625895 genotype in 384 DLBCL patients. The relationship between rs1625895 polymorphisms and the clinical characteristics, first-line therapeutic effects and the prognosis of the patients were analyzed.RESULTS:Among all the patients, 2 (0.5%) patients with AA genotype, 34 (8.9%) patients with AG genotype and 348 (90.6%) patients with GG genotype were identified. The patients with different rs1625895 genotypes did not have any difference in terms of age, gender, B symptoms (developing any of the following symptoms: unexplained recurrent fever (often above 38 °C), night sweats, and unexplained weight loss of 10% within 6 months ), erythrocyte sedimentation rate (ESR), international prognostic index (IPI) and molecular subtype (P>0.05). The overall response rate (ORR) was 82.9% and 82.8% in AA/AG and GG, respectively. There was no significant difference between the first-line therapeutic effects of the two groups (P>0.05). And there was also no difference between A allele carriers and homozygous G allele carriers for the 5-year progressionfree survival rate (PFS) (71.8% vs. 62.3%, χ2=1.351, P=0.245) and 5-year overall survival rate (OS) (72.2% vs. 64.1%, χ2=1.267, P=0.260). But in the subgroup with Germinal Center B-cell (GCB) type, the patients carrying A allele for rs1625895 had an obviously longer PFS (91.7% vs. 72.7%, χ2=4.493, P=0.034) and OS (91.7% vs. 76.7%, χ2=4.246, P=0.039) compared with the patients homozygous for the G allele. As for the patients with non-GCB subtype, there was no significant difference in PFS and OS between different rs1625895 genotypes (P>0.05). According to whether the first-line regimen contained rituximab or not, the patients were divided into two groups treated with cyclophosphoramide, doxorubicin, vincristine and prednisone (CHOP) or with rituximab and CHOP (R-CHOP). But in both subgroups, there was no significant difference in the 5-year PFS and OS between the AA/AG and GG patients, too (P>0.05).CONCLUSION:For DLBCL patients receiving CHOP regimen chemotherapy in the first line, p53 rs1625895 cannot predict the clinical efficacy and prognosis of the patients, but in the patients with GCB subtype, this polymorphism may be a prognostic indicator.

THE ASSOCIATION OF PDCD5 POLYMORPHISMS WITH CLINICOPATHOLOGIC CHARACTERISTICS AND PROGNOSIS IN PATIENTS WITH BREAST CANCER

[Association of XPC gene polymorphisms with breast cancer risk].

The Association Between Polymorphisms in the PDCD1 Gene and the Risk of Cancer: A PRISMA-compliant Meta-Analysis.

Polymorphism of the Programmed Death-Ligand 1 Gene is Associated with Its Protein Expression and Prognosis in Gastric Cancer

Prognostic Value of PDCD6 Polymorphisms and the Susceptibility to Bladder Cancer

Association of the Programmed Cell Death-1 PD1.5 C>T Polymorphism with Cervical Cancer Risk in a Chinese Population.

P53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer.

[Relationship Between P53 Rs1625895 Polymorphism and Prognosis in Diffuse Large B-cell Lymphoma].

The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population.

Association between p53 codon 72 polymorphism and curative ef-fect of postoperative chemo-radiotherapy for breast cancer

Association of P73 G4c14-To-A4t14 (gc/at) Polymorphism with Breast Cancer Survival

Association of BRCA1 K1183R polymorphism with survival in BRCA1/2-negative chinese familial breast cancer.

Association of Rs1008805 Polymorphism in the Cyp19a1 Gene with the Prognosis of Early Breast Cancer.

PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study.

Polymorphisms in PARP1 Predict Disease-Free Survival of Triple-Negative Breast Cancer Patients Treated with Anthracycline/taxane Based Adjuvant Chemotherapy

Prevalence of protein C receptor (PROCR) is associated with inferior clinical outcome in Breast invasive ductal carcinoma.

Association of Genetic Polymorphisms in CDH1 and CTNNB1 with Breast Cancer Susceptibility and Patients' Prognosis among Chinese Han Women.

The Relation Between Expression of P16, P53, CDK4/cyclinD1 and Prognosis in Breast Cancer Cells

Prognostic value and immunological role of PDCD1 gene in pan-cancer

Correlation between mRNA expression of protocadherin-10 and prognosis in gastric cancer

Impact of the PARP1 rs1136410 and rs3219145 polymorphisms on susceptibility and clinicopathologic features of breast cancer in a Chinese population